By Leonid Schneider, on research integrity, biomedical ethics and academic publishing
What with the EU phase 2 clinical trial TETRA going nowhere, the technology’s owner, Liverpool-based company Videregen decided to seek new clinical partners. Surgeons and universities from outside the EU are invited to test Videregen’s trachea transplant technology, which was originally developed together with Paolo Macchiarini by the UCL laryngologist and paid Videregen advisor Martin Birchall.
Imagine you are Martin Birchall, laryngologist and ENT surgeon, star of regenerative medicine at UCL and trachea transplant enthusiast. You and your business partner Videregen need to explain to EU bureaucrats why your technology of decellurised cadaveric trachea is perfectly safe, what with all the dead patients of yours and your former best friend Paolo Macchiarini. Yet both your trachea transplant pigs die. EU authorities however accept this as proof that your method is safe!
The University of Iceland in Reykjavik previously published an external investigation report into the first ever plastic trachea transplant, performedContinue Reading
The European Commission admitted that their €6.8 mn phase 2 clinical trial TETRA with cadaveric tracheas, led by the UCL laryngologist Martin Birchall is unlikely to ever recruit any patients. In January 2019, the status was changed to “grant agreement terminated”
English version below. El 12 de junio de 2008, el cirujano torácico y entusiasta de la medicina regenerativa Paolo MacchiariniContinue Reading
Bad news for regenerative medicine enthusiasts, the data manipulating biologist Suchitra Sumitran-Holgersson and her surgeon partner Michael Olausson, both professors atContinue Reading
The stem cell pioneering surgeon Paolo Macchiarini is back in court now. No, he is not the accused this time.Continue Reading
The European Union Commission staunchly refuses to tell me what exactly their funded scientists intend to do to the scheduledContinue Reading
The Science and Technology Committee of the British House of Commons is now dealing with the trachea transplants performed byContinue Reading
Swedish start-up Verigraft received €2.2 Million from European Union, to further develop regenerative medicine technology tainted by research misconduct and patient abuse. The founder of this very company: Suchitra Sumitran-Holgersson. A clinical trial is scheduled based on debunked science of recellurising dead blood vessel grafts.
For Better Science